Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo
- PMID: 2009529
Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo
Abstract
Müllerian inhibiting substance (MIS) causes regression of the müllerian duct in the male fetus. Bovine MIS has been reported to inhibit the growth of some gynecological tumors. Recombinant human MIS (rhMIS) produced in transfected Chinese hamster ovary cells has been highly purified by immunoaffinity chromatography. The introduction of a salt wash prior to elution of MIS from the affinity column removes a growth-stimulating factor(s) derived from Chinese hamster ovary cells. This immunopurified rhMIS caused significant inhibition (34-59% survival) of A431 (a vulvar epidermoid carcinoma), HT-3 (a cervical carcinoma), HEC-1-A (an endometrial adenocarcinoma), NIH:OVCAR-3 (an ovarian adenocarcinoma), and OM431 (an ocular melanoma) human cell lines in colony inhibition assays. Two cell lines, Hep 3B (a hepatocellular carcinoma) and RT4 (a bladder transitional cell papilloma), were unresponsive to immunopurified rhMIS. Using an in vivo subrenal capsule assay in irradiated CD-1 mice, the growth of A431 and OM431 cells was inhibited by immunopurified rhMIS. We conclude that rhMIS inhibits the growth of certain tumor cell lines in vitro and in vivo.
Similar articles
-
Recombinant human mullerian inhibiting substance inhibits human ocular melanoma cell lines in vitro and in vivo.Cancer Res. 1992 Mar 1;52(5):1182-6. Cancer Res. 1992. PMID: 1531323
-
Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.Cancer Res. 1989 Apr 15;49(8):2005-11. Cancer Res. 1989. PMID: 2702642
-
Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.Clin Cancer Res. 2006 Mar 1;12(5):1593-8. doi: 10.1158/1078-0432.CCR-05-2108. Clin Cancer Res. 2006. PMID: 16533786
-
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.Mol Cell Endocrinol. 2003 Dec 15;211(1-2):37-42. doi: 10.1016/j.mce.2003.09.009. Mol Cell Endocrinol. 2003. PMID: 14656474 Review.
-
Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.Recent Prog Horm Res. 2000;55:53-67; discussion 67-8. Recent Prog Horm Res. 2000. PMID: 11036933 Review.
Cited by
-
Anti-Müllerian hormone: biology and role in endocrinology and cancers.Front Endocrinol (Lausanne). 2024 Sep 16;15:1468364. doi: 10.3389/fendo.2024.1468364. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39351532 Free PMC article. Review.
-
HEC-1 cells.Hum Cell. 2002 Jun;15(2):81-95. doi: 10.1111/j.1749-0774.2002.tb00103.x. Hum Cell. 2002. PMID: 12227503 Review.
-
Mullerian inhibiting substance inhibits invasion and migration of epithelial cancer cell lines.Gynecol Oncol. 2011 Jan;120(1):128-34. doi: 10.1016/j.ygyno.2010.09.017. Epub 2010 Nov 6. Gynecol Oncol. 2011. PMID: 21056908 Free PMC article.
-
Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA expression in the healthy and cancerous endometria.Oncol Lett. 2019 Jan;17(1):532-538. doi: 10.3892/ol.2018.9565. Epub 2018 Oct 10. Oncol Lett. 2019. PMID: 30655798 Free PMC article.
-
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.Int J Oncol. 2011 Oct;39(4):811-20. doi: 10.3892/ijo.2011.1042. Epub 2011 May 13. Int J Oncol. 2011. PMID: 21573503 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources